Two moon missions touched down on the lunar surface. How they unfolded was a stark contrast
Editor's note: A version of this story appeared in CNN's Wonder Theory science newsletter. To get it in your inbox, sign up for free here.
Each time a robotic explorer launches from Earth, it faces innumerable challenges — any of which could cut the mission short.
California-based asteroid mining company AstroForge shared on Thursday that its Odin spacecraft, which ventured to space a week and a half ago with Intuitive Machines' Athena lunar lander, met an untimely end.
The probe was heading for an asteroid to scout for the valuable resource platinum. But Odin's team said the vehicle is likely tumbling through space, with little hope of restoring communications.
Space is hard, and every bold mission adds lessons learned. This week, a tale of two lunar landers demonstrates why scientists and engineers always expect the unexpected in the saga of space exploration.
On March 2, Firefly Aerospace's Blue Ghost lunar lander touched down on the moon, making it the second private sector company to execute the feat.
Photos showcasing the spacecraft's dramatic shadow on the lunar surface and its feet within moon dust confirmed the mission's success.
The Cedar Park, Texas-based company has since shared a video of the lander's nail-biting descent just north of the moon's equator.
Blue Ghost will spend the next week collecting samples, drilling into the subsurface and capturing high-definition imagery.
The Athena lander also made it to the moon, after descending near the lunar south pole on Thursday in hopes of conducting a water-finding mission.
Initially, Intuitive Machines was scrambling to determine the spacecraft's orientation. But images from Athena's suite of cameras helped confirm that the mission ended prematurely, with the lander lying on its side inside a crater.
The lander is 820 feet (250 meters) from the target landing site of Mons Mouton, a flat-topped mountain, the Houston-based company said.
Before powering down, Athena briefly operated and transmitted data, making it the 'southernmost lunar landing and surface operations ever achieved,' according to the company.
Meet the woolly mouse, genetically modified to have several woolly mammoth-like traits.
Engineered by Colossal Biosciences, the mice have curly whiskers and hair that grows three times longer than that of typical lab mice.
Colossal is attempting to resurrect mammoths and other extinct creatures, and the mice will enable its team to test links between specific genetic sequences and physical traits that enabled the giants to endure bitterly cold environments, according to the private Dallas company.
But the new study doesn't address whether the modified mice are actually tolerant of the cold, said Robin Lovell-Badge, head of the Stem Cell Biology and Developmental Genetics Laboratory at The Francis Crick Institute in London.
'As it is, we have some cute looking hairy mice, with no understanding of their physiology, behaviour, etc,' Lovell-Badge said via email.
The adventure of the world's biggest iceberg, known as A23a, may have come to an end after it spent five years wandering the Southern Ocean near Antarctica and, for a time, spinning around an undersea mountain.
The 'megaberg,' weighing 1.1 trillion tons (nearly 1 trillion metric tonnes) and slightly smaller than Rhode Island, ran aground on the island of South Georgia in the southern Atlantic Ocean.
'Nutrients stirred up by the grounding and from its melt may boost food availability for the whole regional ecosystem, including for charismatic penguins and seals,' said Andrew Meijers, an oceanographer at the British Antarctic Survey.
Now, scientists are trying to predict what will happen to A23a next, and what impact the iceberg will have if it splits into pieces.
Archaeologists have uncovered a cache of tools that ancient human ancestors crafted from elephant and hippopotamus bones 1.5 million years ago in Olduvai Gorge, known as the 'Cradle of Humankind,' in Tanzania.
The unexpected discovery makes these the oldest known bone tools by about 1 million years. The 27 bone fragments appear to have been systematically sharpened and shaped using stone.
Researchers believe our early human ancestors took the same sophisticated techniques they used to make stone tools and applied them to carefully selected limb bones from large animals.
The finding suggests that hominins were capable of critical thinking and innovative craftsmanship, but scientists are still trying to figure out who exactly made the tools.
Let your curiosity ascend to new heights with these stories:
— For the second time this year, SpaceX's megarocket Starship exploded midflight during a test mission, disrupting air traffic and raining down flaming debris that was captured on video by onlookers in the Caribbean.
— The narwhal is often called the 'unicorn of the sea' because of its signature spiral tusk. Now, scientists have recorded the first video evidence revealing some surprising ways the Arctic whales use their tusks, including for playful behavior.
— The twin Voyager probes are each turning off a science instrument to conserve power and prevent both historic missions from ending within a few months.
Like what you've read? Oh, but there's more. Sign up here to receive in your inbox the next edition of Wonder Theory, brought to you by CNN Space and Science writers Ashley Strickland, Katie Hunt and Jackie Wattles. They find wonder in planets beyond our solar system and discoveries from the ancient world.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030
The human microbiome-based drugs and diagnostics market is projected to grow from $393.4M in 2025 to $1.2B by 2030, at a CAGR of 25.6%. Key players include Ferring, Nestlé Health Science, and Vedanta Biosciences. The report covers market trends, competitive landscape, and ESG developments. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Human Microbiome-based Drugs and Diagnostics: Global Markets" report has been added to global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030. The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) microbiome-based drugs and diagnostics are novel approaches to tackling difficult-to-treat diseases. The growing understanding of the human microbiome can be leveraged to fill the gaps in conventional treatment options. A wide range of scientific studies have demonstrated the role of microbiomes in the pathogenesis of various diseases. The microbiome field is also witnessing an increased level of investments from the private and public sectors. Future opportunities in the market lie in exploring microbiomes in other body parts, such as lungs, and developing microbiome-based drugs as combination therapies. Leading companies in the market for human microbiome-based drugs and diagnostics include Ferring, Nestle Health Science (Seres Therapeutics), BiomeBank, Genetic Analysis AS and Vedanta Scope 55 data tables and 51 additional tables Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes An analysis of the key patent grants and recently published patents Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook Profiles of the leading companies, including Ferring Pharmaceuticals, Nestle Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc. Companies Featured BiomeBank EnteroBiotix Ltd. Enterome Ferring Genetic Analysis Illumina Inc. Microbiome Insights Microbiotica Nestle Health Science Oxford Nanopore Technologies plc PacBio SFA Therapeutics Inc. Thermo Fisher Scientific Inc. Vedanta Biosciences Inc. Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Market Dynamics Emerging Technologies Analysis by Segment Regional Analysis Conclusion Chapter 2 Market Overview Overview and Market Definition Different Microbiomes in Humans Microbiome, Human Health and Disease Technologies Aiding Microbiome Research Culturing and Cultivation Strategies for the Development of Microbiome Therapeutics Additive Microbiome Therapy Modulatory Microbiome Therapy Analysis of Macroeconomic Factors Geopolitical Factors Inflation and Currency Exchange Fluctuations Porter's Five Forces Analysis Chapter 3 Market Dynamics Takeaways Market Drivers Growing Evidence of Microbiome-disease Correlation Microbiome-based Diagnostics for Disease Prevention and Monitoring Market Restraints Challenges in Clinical Trial Design Lack of Established Regulatory Frameworks High Costs of Microbiome Therapeutics Market Opportunities Direct-to-Consumer Microbiome Testing Drugs and Diagnostics for Lung and Skin Microbiomes Chapter 4 Regulatory Landscape Regulatory Aspects North America Europe Asia-Pacific Chapter 5 Emerging Technologies Takeaways Emerging Technologies Microbial Ecosystem Therapeutics Metatranscriptome Sequencing Genetically Modified Microbiome Therapeutics Combination and Adjuvant Therapies with Microbiome-based Drugs Novel Preclinical Models Chapter 6 Market Segmentation Analysis Segmentation Breakdown Market Analysis by Type Microbiome-based Drugs Market Analysis by Application Infectious Diseases GI Disorders Metabolic Disorders Cancer Other Diseases Market Analysis by End User Hospitals and Clinics Research Institutions Pharmaceutical Companies Geographic Breakdown Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Takeaways Company Share Analysis Competitive Analysis Venture Funding and Investment Landscape Recent Developments Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective Introduction to ESG ESG Risk Ratings Concluding Remarks Chapter 9 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio


Medscape
an hour ago
- Medscape
Could Liquid Biopsy Guide Treatment in Cervical Cancer?
Circulating tumor DNA (ctDNA) levels in patients with cervical cancer before and during treatment were prognostic of disease progression and survival in a post hoc analysis of the phase 3 CALLA trial. The findings 'support the future utility of…ctDNA analysis to help guide treatment decisions for locally advanced cervical cancer,' said lead study author Jyoti Mayadev, MD, a radiation oncologist at Moores NCI-Designated Comprehensive Cancer Center and professor of radiation medicine and applied sciences at the University of California, San Diego School of Medicine in La Jolla, California. Mayadev reported the results at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. They were published simultaneously in the Annals of Oncology . The previously published CALLA trial showed that patients receiving adjuvant chemoradiotherapy (CRT) for locally advanced cervical cancer did not have improved progression-free survival (PFS) with the addition of concurrent durvalumab compared with placebo. The trial included 770 patients with previously untreated stage IB2-IIB node-positive or IIIA-IVA any node-status locally advanced cervical cancer who were randomly assigned to receive durvalumab (1500 mg intravenously once every 4 weeks) plus CRT (n = 385) or CRT alone (n = 385). CRT, consisting of external beam radiotherapy with intravenous cisplatin or carboplatin, was delivered once weekly for 5 weeks, followed by image-guided brachytherapy. Exploratory Analysis Methods and Results A preplanned exploratory analysis sampled ctDNA levels in a subset of 186 patients to determine if ctDNA could serve as a biomarker for treatment response. The study used an ultrasensitive tumor-informed ctDNA assay, personalized for each patient, to test plasma at baseline, cycle 3 day 1 (immediately post-CRT), and cycle 6 day 1 (3 months post-CRT), explained Mayadev during her presentation at the meeting. ctDNA was detected in 99% of baseline samples, with no difference across the treatment arms, she reported. Immediately after treatment, detectable levels decreased to 35.5% in the durvalumab/CRT arm and 39.8% in the CRT-only arm. By 3 months after treatment, levels declined further to 23.4% and 36.4%, respectively, demonstrating a 13% lower rate of detectable ctDNA in the durvalumab/CRT arm at this timepoint. The study showed that ctDNA levels were prognostic of both PFS and overall survival (OS), regardless of treatment arm. Among patients in whom ctDNA was detectable immediately posttreatment, 68% subsequently progressed, and among those without detectable ctDNA, 83% had not progressed by the time of data cutoff, for a positive predictive value of 61%, a negative predictive value of 83%, and a sensitivity and specificity of 68% and 78%, respectively. ctDNA Detected 5.5 Months Before Radiographic Progression The median lead time from ctDNA detection on the ultrasensitive assay until radiographic or clinical evidence of progression was 5.5 months, ranging from 1.5 to 16.5 months. Looking specifically at PFS and OS, patients with ctDNA levels were prognostic of PFS and OS for patients in both treatment arms at all timepoints measured. In the durvalumab/CRT arm, low vs high ctDNA at baseline conferred a hazard ratio of 0.60 for PFS and of 0.63 for OS. In the CRT-only arm, low vs high ctDNA conferred hazard ratios of 0.62 and 0.85 for PFS and OS, respectively. Similarly, detectable ctDNA levels immediately posttreatment compared with undetectable levels identified patients at a higher risk for progression and death, regardless of treatment arm. With detectable ctDNA as the reference, PFS and OS hazard ratios were 0.23 and 0.20 in the durvalumab/CRT arm and 0.15 and 0.18 in the CRT-only arm, respectively. Having no ctDNA detected 3 months after treatment cessation reduced the risks for progression and death by at least 95% for patients in both treatment arms, Mayadev said during her presentation. Multivariate analysis showed that detection of ctDNA immediately posttreatment conferred a hazard ratio of 5.27 ( P < .001) for PFS, independent of disease stage at baseline or treatment allocation, she said. 'Our study found that persistent ctDNA levels posttreatment strongly correlated with an increased risk of relapse and were likely reflective of residual disease that, in some instances, went undetected by other means,' wrote Mayadev and co-authors in their paper. 'On average, ctDNA was detected 5.5 months before radiographic progression. In clinical practice, this could allow for proactive treatment management to potentially improve patient outcomes — for example, earlier consideration of adjuvant therapies, such as immunotherapy or systemic therapy, or a switch to a novel therapeutic regimen. In cases of recurrence, tracking ctDNA levels in real-time could also help assess response to salvage therapy, providing a dynamic tool for optimizing therapeutic decisions.' 'This really is a good analysis showing how ctDNA is definitely a better prognostic marker than standard poor prognostic clinical factors such as nodal status and even updated FIGO staging for cervical cancer,' said Mark Einstein, MD, the discussant for the paper, who is professor and chair of the Department of Obstetrics and Gynecology and Women's Health at Montefiore Medical Center/Albert Einstein College of Medicine, New York City. However, he said the positive predictive value and sensitivity 'are good, but they're not great. The negative predictive value, though, is excellent, and this would reveal that the test might have some value as a negative predictive marker of recurrence rather than a positive predictive marker of recurrence.' But, the bigger question, he said, is 'what are we going to do with that information? If we actually do know that someone has a positive ctDNA, are we going to get into the situation that we are in with ovary cancer, with CA125 without measurable disease, where it just creates a lot of anxiety without necessarily restarting treatment? This could identify central disease before it actually becomes distant, which could lead to potentially curative surgical options, and it might put someone on increased surveillance in imaging, but I think we need to really look at this prospectively.' Also commenting on the study, Sarah Kim, MD, a gynecologic surgeon specializing in the treatment of ovarian, endometrial, cervical, vulvar, and vaginal cancer at the Memorial Sloan Kettering Cancer Center in New York City, pointed out what she found useful and what additional questions need to be answered. 'Further studies need to be done to validate these results and determine the clinical utility in the setting of adjuvant therapy or recurrence,' she said in an interview with Medscape Medical News . 'I think these are important findings and potentially clinically impactful for patients with locally advanced cervical cancer,' said Kim. 'They support the use of ctDNA to detect minimal residual disease and/or the use of ctDNA as a prognostic marker, which is lacking in cervical cancer. We have seen similar results in patients with endometrial cancer, where the ctDNA increases prior to any detection of disease on imaging.' The trial was sponsored by AstraZeneca. Mayadev disclosed leadership roles with the American Brachytherapy Society and NRG Oncology; honoraria from AstraZeneca; consulting or advisory roles with Agenus, AstraZeneca/MedImmune, Merck, Primmune Therapeutics, and Varian Medical Systems; research funding from Varian Medical Systems; and travel, accommodations, and other expenses from Merck. Einstein disclosed a consulting or advisory role with Antiva Biosciences, Asieris Pharmaceuticals, and Merck, and research funding from Johnson & Johnson, Merck, and PapiVax Biotech, Inc. Kim had no disclosures.


CNN
2 hours ago
- CNN
More measles exposures are happening at airports and tourist destinations. Here's what travelers need to know
Vaccines Children's health Aviation newsFacebookTweetLink Follow More than 1,100 measles cases have been reported in the United States this year, and the highly contagious virus has put people at risk while they wait in ERs and doctor's offices — but also at a Shakira concert in New Jersey, at a mall in Minnesota, at a Buc-ee's store in Texas and in airports and planes in several states. 'Travelers can catch measles in many travel settings including travel hubs like airports and train stations, on public transportation like airplanes and trains, at tourist attractions, and at large, crowded events,' the US Centers for Disease Control and Prevention said in a recently updated travel notice. 'Infected travelers can bring the disease back to their home communities where it can spread rapidly among people who are not immune.' It's a situation that may feel unfamiliar for US travelers. In 2000, measles was declared eliminated from the US due to highly effective and coordinated vaccination efforts. That year, only 85 cases were recorded, all of which were imported. But at least 1,157 measles cases have been reported this year, according to a CNN tally using data from state health departments. Only one other year since 2000 has had more cases: 2019, when there were 1,274. The vast majority of this year's cases have been part of an ongoing multistate outbreak centered in West Texas. The outbreak appears to be stabilizing, but there is growing concern around the risk of additional spread due to summer travel, said Lori Tremmel Freeman, chief executive officer for the National Association of County and City Health Officials. At the epicenter of the measles outbreak in Gaines County, 'that community has either become immune by contracting measles and developing immunity from the disease, or in some cases, they've gotten vaccinated,' Freeman said, but she added that 'there's a cautionary tale,' because of summer travel. 'Heavy travel is anticipated,' she warned. 'The travel spread could continue throughout the rest of the country as these groups become mobile and still carry the disease.' The CDC's health notice emphasizes that all international travelers should be fully vaccinated with the recommended two doses of the measles-mumps-rubella (MMR) vaccine and that infants ages 6 months to 11 months who are traveling should receive an extra dose. Dr. Peter Hotez, co-director of the Texas Children's Hospital Center for Vaccine Development, said this recommendation for infants was also given by the Texas Department of State Health Services in the 10 counties that have seen increased measles transmission during this year's outbreak. 'That means, then, that you're going to wind up giving three doses instead of two doses. Usually, you give one dose [to children between] 12 to 15 months, a second dose at 4 to 6 years [old]. Now, you're going to give three doses,' he said. But he emphasized that that this extra dose is still safe: 'The MMR vaccine is one of the safest vaccines we know.' Neither the Texas health department nor the CDC recommends the MMR vaccine for adults born before 1957, Hotez notes, riding on the assumption that measles exposure was common in the first half of the 20th century and that exposure would have led to enduring immunity. However, there are exceptions for health care workers serving a measles outbreak area, for whom two MMR doses are recommended regardless of birth year. Hotez highlights that vaccine recommendations may change as outbreaks continue, stressing the importance of staying aware of updates from local health officials. The MMR vaccine is not recommended for pregnant women, infants younger than 6 months and people who have severely weakened immune systems. Although the risk of exposure is generally low, people who can't be vaccinated should speak with their doctor about their individual risk tolerance, said Dr. Scott Roberts, associate medical director for infection prevention at the Yale School of Medicine. 'A lot of this depends on their access to therapeutics at their travel destination, like are they going to an area where immunoglobulins may be available?' Immunoglobulins, also known as antibodies, are naturally produced by the body as a part of immune responses. They play a crucial role in identifying and neutralizing foreign substances like bacteria and viruses and are specific to each pathogen. People who have a weakened immune system can get immunoglobulins, typically at a hospital or clinic, if they're exposed to measles. Historically, Roberts said, the most common source of US measles outbreaks has been non-immune US residents who traveled abroad, were exposed to the virus and then brought it back. Although some international travelers have brought measles into the US, this makes up a minority of cases. Although no country requires proof of MMR immunization for travel, Roberts advises travelers to 'double-check their immunity status before traveling internationally.' This immunity may involve a prior measles infection, birth before 1957, lab test results of measles immunity or written documentation of MMR immunization. Travelers should check their status at least 6 weeks before they leave, he said. Full immunity includes the two doses of MMR vaccine at least 28 days apart as well as the two weeks it takes to build up final immunity after the last dose. Two doses of the MMR vaccine are 97% effective against measles infection, so vaccinated travelers who suspect that they have been exposed to the virus shouldn't need to worry, Roberts said. Although that leaves a 3% chance of infection, symptoms are significantly lessened with the vaccine. If you are unvaccinated and suspect that you may have been exposed, Roberts says you should see a doctor as soon as possible. 'Depending on how soon you are after exposure, you can still do something,' he said. You may be able to get immunoglobulin or even the MMR vaccine to help lessen symptoms. Other than verifying immunity, Roberts advises typical travel guidance such as packing commonly used and prescribed medications, as well as keeping a list of hospitals or clinics at your destination and other first-aid supplies. When traveling internationally, Roberts recommends checking the country-specific travel health notices on the CDC website to stay aware of additional vaccinations and medications needed for certain destinations. Roberts advises travelers wash their hands frequently, avoid people who are sick when possible, stay in well-ventilated areas and wear masks if they are at high risk of severe illness, staying up to date with vaccinations, especially those who were unable to get vaccinated because of severe immunodeficiency. These practices don't just help prevent measles infection, they help curb infection from other circulating pathogens such as Covid-19 and the flu. Measles is one of the most contagious germs around. In one case 10 years ago, four travelers were infected by a person at the same airport gate. 'This highlights how contagious [measles] is,' Roberts said. 'Even airports and terminals are risky.' The ongoing measles outbreak is not to be taken lightly, Hotez said. 'In the 1980s, measles was the single leading killer of children globally. It [led to] 3 million deaths annually. Now, through the GAVI Vaccine Alliance and other programs, we've brought it down to around 100,000 deaths, but it's still a lot. And we're seeing what happens in West Texas. Ten percent, 20% of kids are being hospitalized, measles, pneumonia, neurologic injury. We've had over 90 hospitalizations so far in Texas and two measles deaths.'